Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward

Hayley Sparks, Gayatri Nair, Alejandro Castellanos, A. Clinton White

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

Cryptosporidiosis is increasingly recognized as an important global health concern. While initially reported in immunocompromised patients such as AIDS patients, cryptosporidiosis has now been documented as a major cause of childhood diarrhea and an important factor in childhood malnutrition. Currently, nitazoxanide is the only proven anti-parasitic treatment for Cryptosporidium infections. However, it is not effective in severely immunocompromised patients and there is limited data in infants. Immune reconstitution or decreased immunosuppression is critical to therapy in AIDS and transplant patients. This limitation of treatment options presents a major public health challenge given the important burden of disease. Repurposing of drugs developed for other indications and development of inhibitors for novel targets offer hope for improved therapies, but none have advanced to clinical studies.

Original languageEnglish (US)
Pages (from-to)181-187
Number of pages7
JournalCurrent Tropical Medicine Reports
Volume2
Issue number3
DOIs
StatePublished - Sep 6 2015

Fingerprint

Cryptosporidium
Cryptosporidiosis
nitazoxanide
Immunocompromised Host
Acquired Immunodeficiency Syndrome
Drug Repositioning
Therapeutics
Malnutrition
Immunosuppression
Diarrhea
Public Health
Transplants
Infection

Keywords

  • Cryptosporidiosis
  • Cryptosporidium
  • Cryptosporidium hominis
  • Cryptosporidium parvum
  • Nitazoxanide
  • Paromomycin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Treatment of Cryptosporidium : What We Know, Gaps, and the Way Forward. / Sparks, Hayley; Nair, Gayatri; Castellanos, Alejandro; White, A. Clinton.

In: Current Tropical Medicine Reports, Vol. 2, No. 3, 06.09.2015, p. 181-187.

Research output: Contribution to journalReview article

@article{6ce87b58282a4458ad3b4c3f8abf7402,
title = "Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward",
abstract = "Cryptosporidiosis is increasingly recognized as an important global health concern. While initially reported in immunocompromised patients such as AIDS patients, cryptosporidiosis has now been documented as a major cause of childhood diarrhea and an important factor in childhood malnutrition. Currently, nitazoxanide is the only proven anti-parasitic treatment for Cryptosporidium infections. However, it is not effective in severely immunocompromised patients and there is limited data in infants. Immune reconstitution or decreased immunosuppression is critical to therapy in AIDS and transplant patients. This limitation of treatment options presents a major public health challenge given the important burden of disease. Repurposing of drugs developed for other indications and development of inhibitors for novel targets offer hope for improved therapies, but none have advanced to clinical studies.",
keywords = "Cryptosporidiosis, Cryptosporidium, Cryptosporidium hominis, Cryptosporidium parvum, Nitazoxanide, Paromomycin",
author = "Hayley Sparks and Gayatri Nair and Alejandro Castellanos and White, {A. Clinton}",
year = "2015",
month = "9",
day = "6",
doi = "10.1007/s40475-015-0056-9",
language = "English (US)",
volume = "2",
pages = "181--187",
journal = "Current Tropical Medicine Reports",
issn = "2196-3045",
publisher = "Springer International Publishing AG",
number = "3",

}

TY - JOUR

T1 - Treatment of Cryptosporidium

T2 - What We Know, Gaps, and the Way Forward

AU - Sparks, Hayley

AU - Nair, Gayatri

AU - Castellanos, Alejandro

AU - White, A. Clinton

PY - 2015/9/6

Y1 - 2015/9/6

N2 - Cryptosporidiosis is increasingly recognized as an important global health concern. While initially reported in immunocompromised patients such as AIDS patients, cryptosporidiosis has now been documented as a major cause of childhood diarrhea and an important factor in childhood malnutrition. Currently, nitazoxanide is the only proven anti-parasitic treatment for Cryptosporidium infections. However, it is not effective in severely immunocompromised patients and there is limited data in infants. Immune reconstitution or decreased immunosuppression is critical to therapy in AIDS and transplant patients. This limitation of treatment options presents a major public health challenge given the important burden of disease. Repurposing of drugs developed for other indications and development of inhibitors for novel targets offer hope for improved therapies, but none have advanced to clinical studies.

AB - Cryptosporidiosis is increasingly recognized as an important global health concern. While initially reported in immunocompromised patients such as AIDS patients, cryptosporidiosis has now been documented as a major cause of childhood diarrhea and an important factor in childhood malnutrition. Currently, nitazoxanide is the only proven anti-parasitic treatment for Cryptosporidium infections. However, it is not effective in severely immunocompromised patients and there is limited data in infants. Immune reconstitution or decreased immunosuppression is critical to therapy in AIDS and transplant patients. This limitation of treatment options presents a major public health challenge given the important burden of disease. Repurposing of drugs developed for other indications and development of inhibitors for novel targets offer hope for improved therapies, but none have advanced to clinical studies.

KW - Cryptosporidiosis

KW - Cryptosporidium

KW - Cryptosporidium hominis

KW - Cryptosporidium parvum

KW - Nitazoxanide

KW - Paromomycin

UR - http://www.scopus.com/inward/record.url?scp=84981518734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981518734&partnerID=8YFLogxK

U2 - 10.1007/s40475-015-0056-9

DO - 10.1007/s40475-015-0056-9

M3 - Review article

AN - SCOPUS:84981518734

VL - 2

SP - 181

EP - 187

JO - Current Tropical Medicine Reports

JF - Current Tropical Medicine Reports

SN - 2196-3045

IS - 3

ER -